People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology, Medical Devices, Biotech / Pharma, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cytek BioSciences, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.5B | 2020 |
| NanoCellect Biomedical, Inc. | — | Biotechnology | Series B | $58.6M | $322.6M | 2016 |
| Celsee Diagnostics, Inc. | — | Medical Devices | Series B | $40.5M | $135.3M | 2015 |
| Carterra, Inc. | — | Biotechnology | Series A | $34.5M | $34.5M | 2018 |
| Swift Biosciences, Inc. | — | Biotech / Pharma | Series A | $31.5M | $134.0M | 2018 |
| KromaTiD, Inc. | — | Other | Series A | $16.0M | $12.1M | 2024 |
| ViroCyt, LLC | — | Other Health Care | Series A | $14.3M | $70.0M | 2012 |
| Intellicyt Corp | — | Biotechnology | Series A | $13.8M | $196.8M | 2013 |
| Aquaro Histology, Inc. | — | Biotechnology | Series A | $9.8M | $354.7M | 2017 |
| RealBio Technology, Inc. | — | Biotechnology | Seed | $3.1M | $21.5M | 2013 |
Jack Ball at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jack Ball on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Walter Young | 3 | 3 |
| Nathan Wood | 2 | 3 |
| Priyadarshini Gogoi | 2 | 2 |
| John Miller | 1 | 27 |
| ANDREW LEVIN | 1 | 17 |
| PAUL CONLEY | 1 | 17 |
| Mark Lewis | 1 | 15 |
| Dan Watkins | 1 | 8 |
| Gregory Johnson | 1 | 8 |
| DEVAL LASHKARI | 1 | 6 |
| Robert Kline | 1 | 6 |
| Jim Smith | 1 | 6 |
| Gregg Fergus | 1 | 5 |
| Linda Tufts | 1 | 5 |
| Mark Lupa | 1 | 5 |
| Rob Hart | 1 | 5 |
| Roger Newton | 1 | 4 |
| Tim Mayleben | 1 | 4 |
| FENG DENG | 1 | 4 |
| Patrick G. Morand | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.